Stocks News

LAST PRICE
48.2400
TODAY'S CHANGE (%)
Trending Up1.8400 (3.9655%)

Bid / Lots
47.5000/ 1
Ask / Lots
48.1100/ 3
Open / Previous Close
46.6300 / 46.4000
Day Range
Low 45.9800
High 48.5000
52 Week Range
Low 15.6000
High 52.9900
Volume
589,206
below average

Search Criteria

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
Company	Country	Symbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

Nov 15, 2024
- DJ Tarsus Pharmaceuticals Is Maintained at Neutral by Goldman Sachs, from 6:57AM ET on Friday Nov 15, 2024 by Dow Jones
  6:57AM ET on Friday Nov 15, 2024 by Dow Jones
  Companies Mentioned: TARS
  
  Ratings actions from Benzinga: https://www.benzinga.com/quote/TARS/analyst-ratings
  
  (END) Dow Jones Newswires
  
  November 15, 2024 06:57 ET (11:57 GMT)
Nov 14, 2024
- Oppenheimer Adjusts Tarsus Pharmaceuticals Price Target to $65 From $63, Maintains Outperform Rating, from 8:35AM ET on Thursday Nov 14, 2024 by MT Newswires
  8:35AM ET on Thursday Nov 14, 2024 by MT Newswires
  Companies Mentioned: TARS
  08:35 AM EST, 11/14/2024 (MT Newswires) -- Tarsus Pharmaceuticals (TARS) has an average rating of Buy and price targets ranging from $36 to $84, according to analysts polled by Capital IQ. (MT Newswires covers equity, commodity and economic research...
- DJ Tarsus Pharmaceuticals Is Maintained at Outperform by Oppenheimer, from 8:26AM ET on Thursday Nov 14, 2024 by Dow Jones
  8:26AM ET on Thursday Nov 14, 2024 by Dow Jones
  Companies Mentioned: TARS
  
  Ratings actions from Benzinga: https://www.benzinga.com/quote/TARS/analyst-ratings
  
  (END) Dow Jones Newswires
  
  November 14, 2024 08:26 ET (13:26 GMT)
Nov 13, 2024
- Tarsus Pharmaceuticals Q3 Loss Narrows, Revenue Surges, from 4:35PM ET on Wednesday Nov 13, 2024 by MT Newswires
  4:35PM ET on Wednesday Nov 13, 2024 by MT Newswires
  Companies Mentioned: TARS
  04:35 PM EST, 11/13/2024 (MT Newswires) -- Tarsus Pharmaceuticals (TARS) reported a Q3 loss late Wednesday of $0.61 per diluted share, compared with a $1.28 loss a year earlier. Analysts polled by Capital IQ expected a loss of $0.92. Revenue for th...
- -- Earnings Flash (TARS) TARSUS PHARMACEUTICALS Posts Q3 Revenue $48.1M, from 4:12PM ET on Wednesday Nov 13, 2024 by MT Newswires
  4:12PM ET on Wednesday Nov 13, 2024 by MT Newswires
  Companies Mentioned: TARS
  04:12 PM EST, 11/13/2024 (MT Newswires) -- ...

Nov 21, 2024
- DJ NewAmsterdam Pharma Price Target Maintained With a $36.00/Share by Needham, from 4:42AM ET on Thursday Nov 21, 2024 by Dow Jones
  4:42AM ET on Thursday Nov 21, 2024 by Dow Jones
  Companies Mentioned: NAMS
Nov 20, 2024
- DJ NewAmsterdam Pharma Down Over 15%, On Track for Largest Percent Decrease Since June 2023 -- Data Talk, from 2:33PM ET on Wednesday Nov 20, 2024 by Dow Jones
  2:33PM ET on Wednesday Nov 20, 2024 by Dow Jones
  Companies Mentioned: NAMS
- NewAmsterdam Pharma's Anti-Bad Cholesterol Treatment Combination Meets Targets in Phase 3 Trial, from 9:33AM ET on Wednesday Nov 20, 2024 by MT Newswires
  9:33AM ET on Wednesday Nov 20, 2024 by MT Newswires
  Companies Mentioned: NAMS
- Celldex Therapeutics Doses First Patient in Study of Potential Inflammatory Disease Treatment, from 8:56AM ET on Wednesday Nov 20, 2024 by MT Newswires
  8:56AM ET on Wednesday Nov 20, 2024 by MT Newswires
  Companies Mentioned: CLDX
- Celldex Announces First Patient Dosed in Phase 1 Healthy Volunteer Study of CDX-622, a Bispecific Antibody, for the Treatment of Inflammatory Diseases, from 8:01AM ET on Wednesday Nov 20, 2024 by Dow Jones
  8:01AM ET on Wednesday Nov 20, 2024 by Dow Jones
  Companies Mentioned: CLDX
- DJ NewAmsterdam Pharma Phase 3 Drug Combo Study Hits Main Endpoints, from 7:35AM ET on Wednesday Nov 20, 2024 by Dow Jones
  7:35AM ET on Wednesday Nov 20, 2024 by Dow Jones
  Companies Mentioned: NAMS
- NewAmsterdam Pharma Announces Positive Topline Data from Pivotal Phase 3 TANDEM Clinical Trial Evaluating the Fixed-Dose Combination of Obicetrapib 10 mg and Ezetimibe 10 mg in Patients with ASCVD or ASCVD Risk Factors and/or HeFH, from 7:00AM ET on Wednesday Nov 20, 2024 by Dow Jones
  7:00AM ET on Wednesday Nov 20, 2024 by Dow Jones
  Companies Mentioned: NAMS
- DJ Celldex Therapeutics Price Target Maintained With a $80.00/Share by HC Wainwright & Co., from 6:21AM ET on Wednesday Nov 20, 2024 by Dow Jones
  6:21AM ET on Wednesday Nov 20, 2024 by Dow Jones
  Companies Mentioned: CLDX
Nov 18, 2024
- NewAmsterdam Pharma Presents Additional Data from Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia at AHA Scientific Sessions 2024, from 3:20PM ET on Monday Nov 18, 2024 by Dow Jones
  3:20PM ET on Monday Nov 18, 2024 by Dow Jones
  Companies Mentioned: NAMS
Nov 15, 2024
- Structure Therapeutics to Participate in the Jefferies London Healthcare Conference, from 8:30AM ET on Friday Nov 15, 2024 by Dow Jones
  8:30AM ET on Friday Nov 15, 2024 by Dow Jones
  Companies Mentioned: GPCR

Tarsus Pharmaceuticals Inc
NASDAQ:TARSUnited States

Search Criteria

Nov 15, 2024

DJ Tarsus Pharmaceuticals Is Maintained at Neutral by Goldman Sachs, from 6:57AM ET on Friday Nov 15, 2024 by Dow Jones

Nov 14, 2024

Oppenheimer Adjusts Tarsus Pharmaceuticals Price Target to $65 From $63, Maintains Outperform Rating, from 8:35AM ET on Thursday Nov 14, 2024 by MT Newswires

DJ Tarsus Pharmaceuticals Is Maintained at Outperform by Oppenheimer, from 8:26AM ET on Thursday Nov 14, 2024 by Dow Jones

Nov 13, 2024

Tarsus Pharmaceuticals Q3 Loss Narrows, Revenue Surges, from 4:35PM ET on Wednesday Nov 13, 2024 by MT Newswires

-- Earnings Flash (TARS) TARSUS PHARMACEUTICALS Posts Q3 Revenue $48.1M, from 4:12PM ET on Wednesday Nov 13, 2024 by MT Newswires

Peers Headlines

Nov 21, 2024

DJ NewAmsterdam Pharma Price Target Maintained With a $36.00/Share by Needham, from 4:42AM ET on Thursday Nov 21, 2024 by Dow Jones

Nov 20, 2024

DJ NewAmsterdam Pharma Down Over 15%, On Track for Largest Percent Decrease Since June 2023 -- Data Talk, from 2:33PM ET on Wednesday Nov 20, 2024 by Dow Jones

NewAmsterdam Pharma's Anti-Bad Cholesterol Treatment Combination Meets Targets in Phase 3 Trial, from 9:33AM ET on Wednesday Nov 20, 2024 by MT Newswires

Celldex Therapeutics Doses First Patient in Study of Potential Inflammatory Disease Treatment, from 8:56AM ET on Wednesday Nov 20, 2024 by MT Newswires

Celldex Announces First Patient Dosed in Phase 1 Healthy Volunteer Study of CDX-622, a Bispecific Antibody, for the Treatment of Inflammatory Diseases, from 8:01AM ET on Wednesday Nov 20, 2024 by Dow Jones

DJ NewAmsterdam Pharma Phase 3 Drug Combo Study Hits Main Endpoints, from 7:35AM ET on Wednesday Nov 20, 2024 by Dow Jones

NewAmsterdam Pharma Announces Positive Topline Data from Pivotal Phase 3 TANDEM Clinical Trial Evaluating the Fixed-Dose Combination of Obicetrapib 10 mg and Ezetimibe 10 mg in Patients with ASCVD or ASCVD Risk Factors and/or HeFH, from 7:00AM ET on Wednesday Nov 20, 2024 by Dow Jones

DJ Celldex Therapeutics Price Target Maintained With a $80.00/Share by HC Wainwright & Co., from 6:21AM ET on Wednesday Nov 20, 2024 by Dow Jones

Nov 18, 2024

NewAmsterdam Pharma Presents Additional Data from Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia at AHA Scientific Sessions 2024, from 3:20PM ET on Monday Nov 18, 2024 by Dow Jones

Nov 15, 2024

Structure Therapeutics to Participate in the Jefferies London Healthcare Conference, from 8:30AM ET on Friday Nov 15, 2024 by Dow Jones